Vertex Pharmaceuticals Upgraded to “Hold” by TheStreet (VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by research analysts at TheStreet from a “sell” rating to a “hold” rating in a report released on Friday, Analyst Ratings Net reports.
The analysts wrote, “Vertex Pharmaceuticals (VRTX) has been upgraded by TheStreet Ratings from sell to hold. The company’s strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and feeble growth in the company’s earnings per share.”
Separately, analysts at UBS AG upgraded shares of Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Monday, January 6th. They now have a $99.00 price target on the stock, up previously from $84.00. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Vertex Pharmaceuticals presently has an average rating of “Buy” and an average price target of $93.29.
In other Vertex Pharmaceuticals news, CEO Jeffrey Leiden sold 35,944 shares of the stock on the open market in a transaction dated Friday, February 7th. The stock was sold at an average price of $80.00, for a total value of $2,875,520.00. Following the completion of the transaction, the chief executive officer now directly owns 211,481 shares of the company’s stock, valued at approximately $16,918,480. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 2.34% during mid-day trading on Friday, hitting $83.015. 399,142 shares of the company’s stock traded hands. Vertex Pharmaceuticals has a 1-year low of $43.69 and a 1-year high of $89.96. The stock has a 50-day moving average of $78.89 and a 200-day moving average of $74.37. The company’s market cap is $19.408 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, January 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.07. The company had revenue of $351.20 million for the quarter, compared to the consensus estimate of $221.08 million. During the same quarter in the previous year, the company posted ($0.35) earnings per share. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $-2.28 earnings per share for the current fiscal year.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.